🏛️ Verified NIH Record • Updated 2026-08-20

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer (NCT07784959)

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Nuvectis Pharma, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Who can join: Review the eligibility criteria below.

Location: NEXT Virginia — Fairfax, Virginia

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

  • NEXT Virginia — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (201) 627-8129

Email: ebelshaw@nuvectis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in ALK Positive

Explore by condition: All ALK Positive clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗